Pharm Exec Podcast

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.

Today's episode covers the president’s call to lower drug costs for patients, the compliance and operational pressures facing pharmaceutical manufacturers, and a White House plan to restrict treatments discovered in China.

In today’s Pharmaceutical Executive Daily, we cover Lundbeck’s restructuring affecting more than 600 international employees, Novo Nordisk’s global plan to cut 9,000 jobs, and former President Trump’s push to rein in pharmaceutical direct-to-consumer advertising.

In today’s Pharmaceutical Executive Daily, we explore strategies to strengthen pharma sales messaging, the role of AI-driven simulations in field rep training, and the FDA’s updated Green List restricting ingredients used in GLP-1 compounding.

In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major pharmaceutical layoffs shaping 2025, and cover Pfizer’s response to political pressure on COVID-19 vaccine safety evidence.

In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into the evolving GLP-1 market, and Sanofi’s share decline following disappointing Phase III results for Amlitelimab.

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s response to political pressure over COVID-19 vaccine safety data, Cheryl Reicin’s outlook on future GLP-1 investment, and Novartis’ $5.2 billion acquisition of Argo Biopharmaceuticals.

In a turbulent era for biopharma, leadership demands clarity, resilience, and adaptability. In this candid podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, shares high-level insights on what CEOs can do to thrive amid the disruption—from regulatory agility to cultural resilience. The corporate strategy expert explains why the best leaders are the best learners—and how prioritization, honesty, and boldness will separate those who merely survive from those who shape the industry’s future.

In this week’s Pharmaceutical Executive Weekly, we cover CSL’s decision to cut 15% of its U.S. workforce and close 22 plasma centers, Pfizer’s Phase 3 trial failure in sickle cell disease, and Eli Lilly’s new LillyDirect program expanding full-dose Zepbound access for obesity patients.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, discusses strategies to address underrepresentation in phase III psoriasis trials. She also talks about Takeda's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to help improve engagement, address operational barriers by incorporating multicultural imagery, and prioritize sites with diverse patient demographics. She also explains how they've enhanced investigator diversity through educational sessions and multilingual toolkits, and how Takeda aims to expand these efforts globally.

In this Pharmaceutical Executive podcast epsiode, Peter Ax, Founder & CEO of UpScriptHealth, discusses:  The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts.  How digital health platforms, like UpScriptHealth, can help reduce friction and costs in healthcare, potentially offsetting tariff impacts  The importance of telehealth in ensuring medication availability Strategic partnerships between digital health platforms and pharma companies to improve patient care and access and more

In this episode of the Pharmaceutical Executive podcast, Jennifer Butler, Chief Commercial Officer of Pleio, discusses: The threat of misinformation to public health and how emotional appeal plays a part Where patients are turning for trustworthy health information Strategies that can be used to verify information Pharma's role in helping to ensure patients have access to health insights they can trust Why the industry is turning to peer-to-patient platforms,  trusted patient communities, and pharmacies to educate patients What kind of role regulatory agencies should play in the battle against misinformation and much more! Check out our new look and read our February issue here: https://www.pharmexec.com/journals/pharmaceutical-executive/pharmaceutical-executive-february-2025 

In this episode of the Pharmaceutical Executive Podcast, CEO and Founder of Sooth, Ian Baer, is back to discuss:  The growing distrust in social media Why people trust friends and influencers over companies The EMA's departure from X  Concerns about information accessibility The healthcare industry's trust gap  "Dark Social" and SO MUCH MORE! Pharmaceutical Executive has a brand new look! Click through our February issue here: https://www.pharmexec.com/journals/pharmaceutical-executive/pharmaceutical-executive-february-2025 

In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence. By utilizing patient-level data and predictive modeling, AI can identify individual needs and preferences, tailoring interventions to optimize treatment outcomes. This personalized approach addresses the common challenges of medication non-adherence and improves patient outcomes. The discussion highlights the importance of ethical considerations and data privacy when leveraging AI in healthcare. By focusing on patient well-being and using AI responsibly, healthcare providers can significantly enhance patient experiences and improve overall health outcomes.